Loading
A phase 3 trial of Mevrometostat, Enzalutamide in prostate cancer, run by Pfizer, now recruiting.
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. is a phase 3 interventional study registered as NCT06629779 by Pfizer, with 900 participants planned, started 2024-10-22 and due to reach its primary completion in 2026-12-02. Interventions recorded: PF-06821497, Placebo, Enzalutamide. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Mevrometostat, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Mevrometostat, Enzalutamide, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Pfizer (incl. Seagen).
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic castration-resistant prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.